Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease

Nalfurafine hydrochloride, a selective κ-opioid receptor agonist has been approved for pruritus in patients with chronic liver disease. However, not all patients respond to nalfurafine hydrochloride. The aim of this study was to clarify the efficacy of nalfurafine hydrochloride. The subjects were pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawano, Tadamichi, Atsukawa, Masanori, Tsubota, Akihito, Shimada, Noritomo, Toyoda, Hidenori, Takaguchi, Koichi, Tani, Joji, Morishita, Asahiro, Hiraoka, Atsushi, Mikami, Shigeru, Ishikawa, Toru, Okubo, Hironao, Watanabe, Tsunamasa, Okubo, Tomomi, Arai, Taeang, Hayama, Korenobu, Itokawa, Norio, Kondo, Chisa, Iwakiri, Katsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068920/
https://www.ncbi.nlm.nih.gov/pubmed/35508514
http://dx.doi.org/10.1038/s41598-022-11431-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068920/
https://www.ncbi.nlm.nih.gov/pubmed/35508514
http://dx.doi.org/10.1038/s41598-022-11431-1

Ejemplares similares